MaxCyte (LON:MXCT)

MaxCyte (LON:MXCT)

Share Price
112.00 p
-12 (-9.68 %)
Market Cap
£64.17 m
Proactive Investors - Run By Investors For Investors

MaxCyte RNS Release

Notice of Full Year Results

RNS Number : 9554T
MaxCyte, Inc.
26 March 2019



MaxCyte, Inc.

("MaxCyte" or the "Company")


Notice of Full Year Results



Gaithersburg, Maryland - 26 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, will be announcing its full year audited results for the year ended 31 December 2018 on Wednesday, 24 April 2019.


Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call and webcast for analysts at 11.00am BST on the day of the results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF.


During the presentation the Company is expected to confirm strong financial progress over the 2018 period, as outlined in the recent trading update; to provide an overview of the Company's novel and proprietary CARMA cell therapy platform in immuno-oncology and the clinical study, which is now underway, of its first wholly-owned lead CAR therapeutic candidate, MCY-M11; and, to highlight key commercial-stage license agreements with leading biotech companies including Kite Pharma, CRISPR Therapeutics and Precision BioSciences.  


About MaxCyte

MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies. The Company now has more than 70 partnered program licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering potentially more than 30 products with aggregate potential milestones of more than $250M. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit


For further information, please contact:


MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer


+1 301 944 1660

Nominated Adviser and Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

James Stearns



+44 (0)20 7886 2500

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji


+44 (0)203 709 5700

[email protected]


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

MaxCyte Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use